{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:45:42Z","timestamp":1792010742183,"version":"4.4.0"},"reference-count":35,"publisher":"American Society of Clinical Oncology (ASCO)","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Specialty oral anticancer medications (SOAMs) improve survival across blood cancers, but access challenges persist. This study examined approval and fill rates of SOAM prescriptions indicated for blood cancers in a nationwide sample of Medicare and commercially insured patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Using nationwide claims, we identified patients with \u22651 new SOAM prescription during 2022. Outcomes included whether a prescription for a new SOAM was (1) rejected by the insurer, (2) approved but not filled by the patient, or (3) approved and filled, at both initial presentation and within 90 days. Among rejected prescriptions, we examined rejection reasons. Among approved prescriptions, we compared fill rates across out-of-pocket (OOP) cost levels. Adjusted outcomes were estimated using logistic regressions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The study included 12,134 patients (61.0% Medicare, 39.0% commercial) with an SOAM prescription. Initially, very few prescriptions were both approved and filled (9.6%, Medicare; 4.0%, commercial). Insurers initially rejected most prescriptions (64.9% for Medicare, 84.0% for commercial), frequently due to prior authorization or formulary restrictions. By 90 days, approval rates rose to 85.0% (Medicare) and 62.8% (commercial), but many approved prescriptions were never filled; ultimately, only 54.5% of Medicare patients and 45.5% of commercial patients both received insurer approval and filled their prescription. Fill rates dropped sharply when OOP costs exceeded $175 in US dollars (USD), with the lowest rates observed at OOP costs of $500.01\u2013$2,000 USD for Medicare patients (29.2%) and at \u2265$2,000 USD for commercially insured patients (21.6%). Adjusted rates were similar to unadjusted rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>This study found substantial access barriers to SOAMs, particularly among commercially insured patients. Even after insurer approval, many patients never filled their prescription. This highlights the importance of addressing both payer-level restrictions and patient-level affordability challenges to ensure treatment access.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-26-00247","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:00:22Z","timestamp":1790798422000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Insurance and Cost-Related Access Barriers to Specialty Oral Anticancer Medications for Blood Cancers in a Nationwide Sample of Medicare and Commercially Insured Patients"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3263-4337","authenticated-orcid":false,"given":"Jalpa A.","family":"Doshi","sequence":"first","affiliation":[{"name":"University of Pennsylvania, Philadelphia, PA"},{"name":"Leonard Davis Institute of Health Economics, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9943-1319","authenticated-orcid":false,"given":"Pengxiang","family":"Li","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Geng","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5081-063X","authenticated-orcid":false,"given":"Matthew J.","family":"Klebanoff","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, PA"},{"name":"Leonard Davis Institute of Health Economics, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy R.","family":"Pettit","sequence":"additional","affiliation":[{"name":"Independent Consultant, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina A.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Vagelos College of Physicians and Surgeons, Columbia University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7071-6475","authenticated-orcid":false,"given":"Scott F.","family":"Huntington","sequence":"additional","affiliation":[{"name":"Yale University, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2490-4453","authenticated-orcid":false,"given":"John K.","family":"Lin","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"e_1_3_6_2_2","volume-title":"Medicines in Development for Leukemia & Lymphoma: A Report on Cancers of the Blood","author":"PhRMA and Leukemia & Lymphoma Society","year":"2015","unstructured":"PhRMA and Leukemia & Lymphoma Society: Medicines in Development for Leukemia & Lymphoma: A Report on Cancers of the Blood, 2015. http:\/\/phrma-docs.phrma.org\/files\/dmfile\/leukemia-lyphoma-20154.pdf"},{"key":"e_1_3_6_3_2","volume-title":"Drug Approvals and Databases","author":"U.S. Food and Drug Administration","year":"2025","unstructured":"U.S. Food and Drug Administration: Drug Approvals and Databases, 2025. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/drug-approvals-and-databases"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00048-4"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.8262"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S106629"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00606"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP-24-00937"},{"key":"e_1_3_6_9_2","unstructured":"IQVIA: Controlling cancer care: The emergence of formulary exclusions in oncology"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00428"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.012302"},{"key":"e_1_3_6_12_2","first-page":"188","article-title":"Impact of cost sharing on specialty drug utilization and outcomes: A review of the evidence and future directions","volume":"22","author":"Doshi JA","year":"2016","unstructured":"Doshi JA, Li P, Ladage VP, et al: Impact of cost sharing on specialty drug utilization and outcomes: A review of the evidence and future directions. Am J Manag Care 22:188-197, 2016","journal-title":"Am J Manag Care"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2011.000316"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.5091"},{"key":"e_1_3_6_15_2","volume-title":"IDV\u00ae Fact Sheet","author":"Symphony Health Solutions","year":"2021","unstructured":"Symphony Health Solutions: IDV\u00ae Fact Sheet, 2021. https:\/\/symphonyhealth.com\/insights\/idv-fact-sheet"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.3451"},{"key":"e_1_3_6_17_2","first-page":"477","article-title":"Adherence patterns for abiraterone acetate and concomitant prednisone use in patients with prostate cancer","volume":"20","author":"Lafeuille MH","year":"2014","unstructured":"Lafeuille MH, Grittner AM, Lefebvre P, et al: Adherence patterns for abiraterone acetate and concomitant prednisone use in patients with prostate cancer. J Manag Care Spec Pharm 20:477-484, 2014","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1351947"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003030"},{"key":"e_1_3_6_20_2","volume-title":"National Population by Characteristics: 2020-2025","author":"US Census Bureau","unstructured":"US Census Bureau: National Population by Characteristics: 2020-2025. https:\/\/www.census.gov\/data\/tables\/time-series\/demo\/popest\/2020s-national-detail.html"},{"key":"e_1_3_6_21_2","volume-title":"NCPDP Standards Information","author":"National Council for Prescription Drug Programs","unstructured":"National Council for Prescription Drug Programs: NCPDP Standards Information. https:\/\/standards.ncpdp.org\/Access-to-Standards.aspx"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.2005.25.7.909"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.10.003"},{"key":"e_1_3_6_24_2","volume-title":"NCI Comorbidity Index Overview. NIH","author":"National Cancer Institute","unstructured":"National Cancer Institute: NCI Comorbidity Index Overview. NIH. https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/\/considerations\/comorbidity.html"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.38182"},{"key":"e_1_3_6_26_2","article-title":"Cancer provider groups across the country urge congress to pass prior authorization reform","author":"American Society of Clinical Oncology","unstructured":"American Society of Clinical Oncology: Cancer provider groups across the country urge congress to pass prior authorization reform. ASCO Post. https:\/\/ascopost.com\/issues\/october-10-2024\/cancer-provider-groups-across-the-country-urge-congress-to-pass-prior-authorization-reform\/","journal-title":"ASCO Post"},{"key":"e_1_3_6_27_2","volume-title":"Standing Up to Prior Authorization","author":"Lawrence L","unstructured":"Lawrence L: Standing Up to Prior Authorization. ASH Clinical News. https:\/\/ashpublications.org\/ashclinicalnews\/news\/7981\/Standing-Up-to-Prior-Authorization"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2022.07.011"},{"key":"e_1_3_6_29_2","volume-title":"2024 Prior Authorization State Law Chart","author":"American Medical Association","year":"2024","unstructured":"American Medical Association. 2024 Prior Authorization State Law Chart. AMA. 2024. https:\/\/www.ama-assn.org\/system\/files\/prior-authorization-state-law-chart.pdf"},{"key":"e_1_3_6_30_2","volume-title":"Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children\u2019s Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges, Merit-Based Incentive Payment System (MIPS) Eligible Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program","author":"Department of Health and Human Services","unstructured":"Department of Health and Human Services: Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children\u2019s Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges, Merit-Based Incentive Payment System (MIPS) Eligible Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program. Federal Register. https:\/\/www.federalregister.gov\/documents\/2024\/02\/08\/2024-00895\/medicare-and-medicaid-programs-patient-protection-and-affordable-care-act-advancing-interoperability"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200256"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2024.00273"},{"key":"e_1_3_6_33_2","doi-asserted-by":"crossref","unstructured":"Shukla A Lin J Li P et al: Patient assistance for drug cost sharing: Highlighting the variability across pharmaceutical manufacturers of specialty oral anticancer medications for blood cancers. In: NCCN 2026 Annual Conference","DOI":"10.6004\/jnccn.2025.7259"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01788"},{"key":"e_1_3_6_35_2","volume-title":"Medicare 2025 Open Enrollment Research Among Medicare Beneficiaries","author":"Patient Access Network Foundation","year":"2025","unstructured":"Patient Access Network Foundation: Medicare 2025 Open Enrollment Research Among Medicare Beneficiaries, 2025. https:\/\/www.panfoundation.org\/wp-content\/uploads\/2025\/09\/PAN-Medicare-Open-Enrollment-Research-Sept-2025.pdf"},{"key":"e_1_3_6_36_2","volume-title":"The Medicare Prescription Payment Plan: Implementation in 2025 and Implications for 2026","author":"Crum R","unstructured":"Crum R, D\u2019Silva R, Engel T, et al: The Medicare Prescription Payment Plan: Implementation in 2025 and Implications for 2026. Milliman. https:\/\/www.milliman.com\/en\/insight\/medicare-prescription-payment-plan-2025-into-2026"}],"updated-by":[{"DOI":"10.1200\/jco-26-02527","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000}}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-26-00247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:59:42Z","timestamp":1792007982000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-26-00247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":35,"alternative-id":["10.1200\/JCO-26-00247"],"URL":"https:\/\/doi.org\/10.1200\/jco-26-00247","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"2026-01-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"JCO-26-00247"}}